NKTR — Nektar Therapeutics Share Price
Last trade - 00:00- $139.95m
- -$115.28m
- $98.43m
- 41
- 27
- 76
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.3 | ||
| Price to Tang. Book | 2.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.42 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -43.39% | ||
| Return on Equity | -124.1% | ||
| Operating Margin | -106.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 152.91 | 101.91 | 92.06 | 90.12 | 98.43 | 72.97 | 63.12 | -3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Directors
- Robert Chess NEC (64)
- Howard Robin CEO (68)
- Gilbert Labrucherie CFO (50)
- Jillian Thomsen SVF (55)
- Mark Wilson SVP (49)
- Brian Kotzin SVP
- John Northcott SVP (43)
- Dimitry Nuyten SVP (45)
- Jonathan Zalevsky OTH (46)
- Roy Whitfield LED (67)
- Jeff Ajer IND (58)
- Diana Brainard IND (50)
- Myriam Curet IND (64)
- Karin Eastham IND (71)
- R. Scott Greer IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 3rd, 1998
- Public Since
- May 3rd, 1994
- No. of Shareholders
- 143
- No. of Employees
- 61
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 186,103,588
- Address
- 455 Mission Bay Boulevard South, SAN FRANCISCO, 94158
- Web
- https://www.nektar.com/
- Phone
- +1 4154825300
- Auditors
- Ernst & Young LLP
Latest News for NKTR
Upcoming Events for NKTR
Q1 2025 Nektar Therapeutics Earnings Release
Q1 2025 Nektar Therapeutics Earnings Call
Nektar Therapeutics Annual Shareholders Meeting
Nektar Therapeutics Annual Shareholders Meeting
Q2 2025 Nektar Therapeutics Earnings Release
Similar to NKTR
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 22:14 UTC, shares in Nektar Therapeutics are trading at $0.75. This share price information is delayed by 15 minutes.
Shares in Nektar Therapeutics last closed at $0.75 and the price had moved by -54.97% over the past 365 days. In terms of relative price strength the Nektar Therapeutics share price has underperformed the S&P500 Index by -59.4% over the past year.
The overall consensus recommendation for Nektar Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNektar Therapeutics does not currently pay a dividend.
Nektar Therapeutics does not currently pay a dividend.
Nektar Therapeutics does not currently pay a dividend.
To buy shares in Nektar Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.75, shares in Nektar Therapeutics had a market capitalisation of $139.95m.
Here are the trading details for Nektar Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NKTR
Based on an overall assessment of its quality, value and momentum Nektar Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Nektar Therapeutics is $4.92. That is 554.26% above the last closing price of $0.75.
Analysts covering Nektar Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.66 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nektar Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -38.58%.
As of the last closing price of $0.75, shares in Nektar Therapeutics were trading -28.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nektar Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Nektar Therapeutics' management team is headed by:
- Robert Chess - NEC
- Howard Robin - CEO
- Gilbert Labrucherie - CFO
- Jillian Thomsen - SVF
- Mark Wilson - SVP
- Brian Kotzin - SVP
- John Northcott - SVP
- Dimitry Nuyten - SVP
- Jonathan Zalevsky - OTH
- Roy Whitfield - LED
- Jeff Ajer - IND
- Diana Brainard - IND
- Myriam Curet - IND
- Karin Eastham - IND
- R. Scott Greer - IND